Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

Achievement of the second milestone under license agreement with Exelixis Inc.

Read More

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

Read More

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax

Read More

Registration of series K subscription warrants of the Company with the National Depository for Securities

Read More

Publication dates for periodic reports in 2024

Read More

Take-up of series K subscription warrants by the European Investment Bank

Read More

Resignation of a member of the Company’s Supervisory Board from his position

Read More